This company has been marked as potentially delisted and may not be actively trading. Tocagen (TOCA) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock TOCA vs. ZYME, MBX, SBTX, AVTE, NLTX, BIOA, CYBN, VIRI, WHWK, and OSTXShould you be buying Tocagen stock or one of its competitors? The main competitors of Tocagen include Zymeworks (ZYME), MBX Biosciences (MBX), Silverback Therapeutics (SBTX), Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), and OS Therapies (OSTX). Tocagen vs. Its Competitors Zymeworks MBX Biosciences Silverback Therapeutics Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics OS Therapies Zymeworks (NYSE:ZYME) and Tocagen (NASDAQ:TOCA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment. Which has more volatility and risk, ZYME or TOCA? Zymeworks has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Tocagen has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Which has better valuation and earnings, ZYME or TOCA? Tocagen has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Tocagen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$122.87M9.32-$118.67M-$0.97-15.70Tocagen$40K6,613.60-$63.52M-$2.69-4.11 Do insiders & institutionals believe in ZYME or TOCA? 92.9% of Zymeworks shares are held by institutional investors. Comparatively, 21.4% of Tocagen shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 10.9% of Tocagen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media refer more to ZYME or TOCA? In the previous week, Zymeworks had 12 more articles in the media than Tocagen. MarketBeat recorded 12 mentions for Zymeworks and 0 mentions for Tocagen. Zymeworks' average media sentiment score of 1.01 beat Tocagen's score of 0.00 indicating that Zymeworks is being referred to more favorably in the media. Company Overall Sentiment Zymeworks Positive Tocagen Neutral Do analysts prefer ZYME or TOCA? Zymeworks presently has a consensus price target of $21.43, indicating a potential upside of 40.70%. Given Zymeworks' stronger consensus rating and higher possible upside, equities analysts clearly believe Zymeworks is more favorable than Tocagen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90Tocagen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ZYME or TOCA more profitable? Zymeworks has a net margin of -182.75% compared to Tocagen's net margin of -176,433.34%. Zymeworks' return on equity of -23.00% beat Tocagen's return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% Tocagen -176,433.34%-327.74%-111.87% SummaryZymeworks beats Tocagen on 13 of the 17 factors compared between the two stocks. Get Tocagen News Delivered to You Automatically Sign up to receive the latest news and ratings for TOCA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TOCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TOCA vs. The Competition Export to ExcelMetricTocagenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$264.54M$941.20M$5.83B$10.00BDividend YieldN/A4.84%5.28%4.53%P/E Ratio-4.671.1275.6926.28Price / Sales6,613.6026.60544.78188.18Price / CashN/A19.5637.2059.76Price / Book24.586.7511.506.41Net Income-$63.52M-$4.20M$3.28B$270.56M Tocagen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TOCATocagenN/A$11.06-0.6%N/A+46.8%$264.54M$40K-4.6777Gap UpZYMEZymeworks2.3962 of 5 stars$14.01flat$21.43+53.0%+30.2%$1.05B$122.87M-9.35460Positive NewsMBXMBX Biosciences2.8237 of 5 stars$14.73+1.1%$37.63+155.4%N/A$491.62MN/A-3.2236Positive NewsSBTXSilverback TherapeuticsN/A$11.12-4.3%N/A-8.6%$400.97MN/A-4.6083High Trading VolumeAVTEAerovate TherapeuticsN/A$7.62-3.5%N/A-88.9%$220.87MN/A-2.5520News CoveragePositive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.64+6.3%N/A-44.4%$184.58MN/A-6.3290BIOABioAge LabsN/A$4.70+1.1%N/AN/A$168.50M$3.86M0.00N/APositive NewsCYBNCybin2.5738 of 5 stars$5.87-6.0%$85.00+1,349.0%N/A$137.91MN/A-1.3350Positive NewsGap DownHigh Trading VolumeVIRIVirios TherapeuticsN/A$4.81-3.0%$5.00+3.9%+2,607.2%$92.63MN/A-17.825WHWKWhitehawk TherapeuticsN/A$1.81-0.5%N/AN/A$85.31M$25.98M-30.1740Positive NewsGap DownOSTXOS Therapies1.9101 of 5 stars$2.10-5.4%$18.00+757.1%-47.5%$66.45MN/A-2.66N/A Related Companies and Tools Related Companies Zymeworks Alternatives MBX Biosciences Alternatives Silverback Therapeutics Alternatives Aerovate Therapeutics Alternatives Neoleukin Therapeutics Alternatives BioAge Labs Alternatives Cybin Alternatives Virios Therapeutics Alternatives Whitehawk Therapeutics Alternatives OS Therapies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TOCA) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredUnlock Friday's Full Potential: Two Simple Sentences that put profits in investors’ pocketsMost traders stick to the same routine each week. But a little-known market strategy has quietly delivered a 9...Eagle Publishing | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredNVDA: The cracks are beginning to showThe media hasn't caught up to the story yet, but when they do, this stock could leave Nvidia in the dust. I...InvestorPlace | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tocagen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Tocagen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TOCA Stock Alerts